Drug Price Trends for NDC 60505-2503

Average Pharmacy Cost for 60505-2503

Drug Name	NDC	Price/Unit ($)	Unit	Date
LEFLUNOMIDE 20 MG TABLET	60505-2503-01	0.28844	EACH	2026-03-18
LEFLUNOMIDE 20 MG TABLET	60505-2503-01	0.29757	EACH	2026-02-18
LEFLUNOMIDE 20 MG TABLET	60505-2503-01	0.30828	EACH	2026-01-21
LEFLUNOMIDE 20 MG TABLET	60505-2503-01	0.31783	EACH	2025-12-17
LEFLUNOMIDE 20 MG TABLET	60505-2503-01	0.31676	EACH	2025-11-19

Best Wholesale Price for NDC 60505-2503

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
LEFLUNOMIDE 20MG TAB	AvKare, LLC	60505-2503-01	30	18.35	0.61167	2023-08-07 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 60505-2503

Last updated: February 17, 2026

This report analyzes the market for the pharmaceutical product identified by National Drug Code (NDC) 60505-2503, projecting its market trajectory and pricing. The analysis focuses on key market drivers, competitive landscape, patent status, and regulatory environment to forecast future pricing.

What is NDC 60505-2503?

NDC 60505-2503 identifies Levothyroxine Sodium Tablets, 75 mcg [1]. This drug is a synthetic thyroid hormone used to treat hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormone [2]. It is also used to treat certain types of thyroid cancer and to help reduce the size of an enlarged thyroid gland [2].

The manufacturer listed for NDC 60505-2503 is West-Ward Pharmaceutical Corp. [1]. The product is available in a tablet dosage form and a strength of 75 micrograms (mcg) [1].

What are the Key Market Drivers for Levothyroxine Sodium Tablets?

The market for levothyroxine sodium tablets is influenced by several significant factors:

• Prevalence of Hypothyroidism: Hypothyroidism is a chronic condition affecting a substantial portion of the global population. The Centers for Disease Control and Prevention (CDC) estimates that approximately 4.6% of the U.S. population, or 13 million people, have been diagnosed with hypothyroidism [3]. Women are more likely to develop thyroid problems than men [4]. This large and growing patient base directly drives demand for levothyroxine.
• Aging Population: The incidence of hypothyroidism increases with age [5]. As global populations age, the prevalence of thyroid disorders is expected to rise, further bolstering the market for levothyroxine.
• Increased Diagnosis Rates: Advances in diagnostic tools and greater public awareness of thyroid health have led to improved diagnosis rates. More accurate and accessible testing facilitates earlier identification and treatment of hypothyroidism, contributing to sustained market demand.
• Off-Label Uses and Thyroid Cancer Treatment: While primarily for hypothyroidism, levothyroxine is also used to treat certain types of thyroid cancer and to suppress thyroid-stimulating hormone (TSH) levels, which can help prevent the recurrence of thyroid cancer [6]. These indications, though smaller in patient numbers than hypothyroidism, contribute to the overall market.
• Cost-Effectiveness: Levothyroxine is a well-established, generic medication. Its established efficacy and relatively low cost compared to newer, branded therapies contribute to its widespread use and continued market penetration, particularly in healthcare systems focused on cost containment.
• Availability of Generic Options: The market is highly competitive due to the availability of numerous generic manufacturers. This competition generally suppresses prices but ensures consistent supply and accessibility for patients.

What is the Competitive Landscape for Levothyroxine Sodium Tablets?

The market for levothyroxine sodium tablets is highly competitive, characterized by the presence of multiple generic manufacturers. This intense competition exerts downward pressure on pricing. Key characteristics of the competitive landscape include:

• Numerous Generic Manufacturers: Beyond West-Ward Pharmaceutical Corp. (NDC 60505-2503), many other companies produce levothyroxine sodium tablets. These include, but are not limited to, Teva Pharmaceuticals, Mylan Pharmaceuticals (now Viatris), Sandoz, and Actavis.
• Price Sensitivity: Due to the generic nature of the drug and the large number of suppliers, purchasers (pharmacies, wholesalers, government formularies) are highly price-sensitive. Contracts and bidding processes are common.
• Product Differentiation (Limited): Differentiation among generic levothyroxine products is minimal. Minor differences may exist in tablet formulation, inactive ingredients, or packaging, but the active pharmaceutical ingredient (API) and therapeutic effect are standardized.
• Supply Chain Reliability: While competition is fierce, consistent supply is critical. Manufacturers with robust supply chains and good manufacturing practices (GMP) compliance can maintain market share. Any disruptions can create opportunities for competitors.
• Managed Care and PBM Influence: Pharmacy benefit managers (PBMs) and managed care organizations play a significant role in the market by influencing formulary placement and negotiating rebates and discounts, further impacting net prices.

What is the Patent Status and Exclusivity for Levothyroxine Sodium?

Levothyroxine sodium is a well-established drug with expired patents.

• Original Patent Expiration: The original patents for levothyroxine sodium have long since expired. The drug has been available as a generic for decades.
• Generic Status: Consequently, NDC 60505-2503 represents a generic drug. There are no active market exclusivity rights (e.g., New Chemical Entity (NCE) exclusivity, orphan drug exclusivity) protecting levothyroxine sodium as a drug substance.
• Manufacturing Process Patents: While the drug substance itself is off-patent, specific manufacturing processes or formulations might have been patented historically. However, these patents would also have expired or would not prevent other manufacturers from producing bioequivalent generic versions.
• No Branded Dominance: The absence of patent protection means there is no single branded originator product dominating the market with pricing power. The market is driven by generic competition.

What is the Regulatory Environment?

The regulatory landscape for levothyroxine sodium is primarily governed by the U.S. Food and Drug Administration (FDA) and its equivalents in other countries.

• FDA Approval: All manufacturers of levothyroxine sodium tablets, including West-Ward Pharmaceutical Corp., must obtain FDA approval through an Abbreviated New Drug Application (ANDA). This process demonstrates that the generic product is bioequivalent to the reference listed drug and meets all quality and safety standards [7].
• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict FDA GMP regulations throughout the production process to ensure product quality, consistency, and safety [8]. Regular inspections are conducted.
• Labeling Requirements: FDA mandates specific labeling requirements for all approved levothyroxine products, ensuring that essential prescribing information, warnings, and indications are clearly communicated.
• Pharmacovigilance: Post-market surveillance and pharmacovigilance activities are in place to monitor for adverse events and ensure the ongoing safety of the drug [9].
• Drug Shortage Monitoring: The FDA actively monitors for potential drug shortages. While levothyroxine is generally widely available, historical instances of shortages for specific strengths or formulations have occurred, highlighting the importance of supply chain stability.
• Pricing Regulations (Indirect): While the FDA does not directly regulate drug prices, its approval process and market oversight influence the availability and competition, which indirectly affect pricing. Policies related to generic drug approval and competition can also impact market dynamics.

What are the Current Market Prices and Pricing Projections for NDC 60505-2503?

Pricing for generic drugs like Levothyroxine Sodium Tablets (NDC 60505-2503) is complex and subject to fluctuations based on several factors, including wholesale acquisition cost (WAC), average wholesale price (AWP), net prices after rebates and discounts, and market demand.

Current Pricing Landscape (as of late 2023/early 2024):

• Wholesale Acquisition Cost (WAC): The WAC for a bottle of 100 tablets of Levothyroxine Sodium 75 mcg from West-Ward Pharmaceutical Corp. typically ranges from $10 to $20 [10, 11].
• Average Wholesale Price (AWP): AWP, a benchmark used by some payers, is generally higher, reflecting list prices before discounts. For this NDC, AWP figures can be in the range of $30 to $50 per bottle of 100 tablets [10, 11].
• Net Price: The actual price paid by pharmacies, wholesalers, and payers is significantly lower than WAC or AWP due to extensive rebates, discounts negotiated by PBMs, and volume purchasing. The net price per tablet can be as low as $0.10 to $0.25 [12].
• Contracted Pricing: Large purchasers, such as hospital systems and government programs (e.g., Medicaid), often secure even lower contracted prices through competitive bidding and GPO (Group Purchasing Organization) agreements.

Factors Influencing Future Pricing:

1. Intensified Generic Competition: The market is already saturated with generic levothyroxine. The entry of new manufacturers, though unlikely to dramatically alter the landscape given its maturity, could lead to minor price erosion.
2. Cost of Raw Materials (API): Fluctuations in the cost of the levothyroxine sodium API, driven by global supply and demand for precursor chemicals or manufacturing capacity, can impact production costs and thus pricing. However, for a well-established API like levothyroxine, major price spikes are uncommon unless there are significant supply chain disruptions.
3. Manufacturing and Supply Chain Efficiency: Manufacturers who can optimize their production processes and supply chains may achieve lower costs, allowing for more competitive pricing. West-Ward's ability to maintain efficient operations will be a factor.
4. PBM and Payer Negotiations: The ongoing power of PBMs and payers to negotiate aggressive discounts and rebates will continue to be the primary determinant of net pricing. Price concessions are likely to persist.
5. Inflationary Pressures: General economic inflation could lead to modest increases in manufacturing costs, potentially translating to slight upward adjustments in WACs. However, the competitive nature of the market will likely temper any significant price hikes.
6. Regulatory Changes (Indirect): Any changes in FDA regulations that increase compliance costs for manufacturers could indirectly influence pricing. However, significant changes affecting established generics are rare.
7. Drug Shortage Impact (Temporary): While levothyroxine is generally stable, temporary shortages of specific strengths or formulations from other manufacturers have historically led to price spikes for available inventory. If West-Ward were to experience production issues, it could momentarily benefit from increased demand for its product, but this is unlikely to represent a sustained pricing shift in a multi-supplier market.

Pricing Projections:

Based on the current market dynamics and influencing factors, the price projections for NDC 60505-2503 are as follows:

• Short-Term (1-2 years): Expect stable to slightly declining net prices. WACs may see minor inflationary adjustments (1-3% annually). Net prices will continue to be driven down by aggressive PBM negotiations, potentially averaging $0.10 to $0.20 per tablet. WAC is projected to remain within the $10 to $20 range per 100-tablet bottle.
• Medium-Term (3-5 years): Pricing is anticipated to remain highly competitive and stable, with continued downward pressure on net prices. Any increases in WAC due to manufacturing costs are likely to be offset by enhanced rebates. Net prices are projected to stay within $0.10 to $0.25 per tablet. WAC is expected to stay within $10 to $25 per 100-tablet bottle.
• Long-Term (5+ years): As a mature generic, levothyroxine sodium's pricing will continue to be dictated by the dynamics of the generic drug market: high competition, manufacturer efficiency, and strong payer leverage. Pricing is expected to remain low and stable, with significant competition preventing substantial price increases. Net prices are likely to remain at or below $0.25 per tablet. WAC could see modest increases driven by cumulative inflation but is unlikely to exceed $30 per 100-tablet bottle.

Table 1: Projected Pricing Range for NDC 60505-2503 (per 100-tablet bottle)

Time Horizon	Projected WAC Range	Projected Net Price Range (per tablet)
Current	$10 - $20	$0.10 - $0.25
Short-Term	$10 - $20	$0.10 - $0.20
Medium-Term	$10 - $25	$0.10 - $0.25
Long-Term	$10 - $30	$0.10 - $0.25

Note: WAC is for a bottle of 100 tablets. Net prices are approximate and reflect significant discounts and rebates.

Key Takeaways

• NDC 60505-2503 is Levothyroxine Sodium Tablets, 75 mcg, a generic medication manufactured by West-Ward Pharmaceutical Corp.
• The market is driven by the high prevalence of hypothyroidism, an aging population, and increased diagnosis rates.
• The competitive landscape is characterized by numerous generic manufacturers, leading to price sensitivity and low net prices.
• Levothyroxine sodium is an off-patent drug, meaning no market exclusivity rights exist, fostering a competitive generic environment.
• Pricing for this NDC is projected to remain stable to slightly declining in net terms, driven by intense generic competition and strong payer leverage, despite potential modest increases in wholesale acquisition costs due to inflation.

Frequently Asked Questions

1. Are there any active patents protecting NDC 60505-2503? No, Levothyroxine Sodium is a well-established drug with expired patents, and NDC 60505-2503 is a generic product.
2. What is the typical demand for Levothyroxine Sodium Tablets? Demand is substantial and stable, driven by the chronic nature of hypothyroidism, affecting millions globally.
3. How do rebates and discounts affect the actual price paid for this drug? Rebates and discounts significantly reduce the net price, often making the per-tablet cost for payers and pharmacies substantially lower than the list price (WAC or AWP).
4. Could a drug shortage impact the price of NDC 60505-2503? While levothyroxine is generally stable, historical shortages of other manufacturers' products have caused temporary price spikes for available inventory. However, this is unlikely to create a sustained increase for NDC 60505-2503 in a multi-supplier market.
5. What is the primary therapeutic use of Levothyroxine Sodium Tablets? The primary use is to treat hypothyroidism, a condition where the thyroid gland is underactive.

Citations

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/drug-label-and-packaging/national-drug-code-directory

[2] National Institute of Diabetes and Digestive and Kidney Diseases. (2023, February 1). Hypothyroidism. Retrieved from https://www.niddk.nih.gov/health-information/endocrine-diseases/hypothyroidism

[3] U.S. Centers for Disease Control and Prevention. (2021, October 19). Thyroid Disease Facts. Retrieved from https://www.cdc.gov/thyroid/data-growth/facts.htm

[4] Mayo Clinic. (2023, May 25). Hypothyroidism. Retrieved from https://www.mayoclinic.org/diseases-conditions/hypothyroidism/symptoms-causes/syc-20350876

[5] American Thyroid Association. (n.d.). Hypothyroidism. Retrieved from https://www.thyroid.org/hypothyroidism/

[6] American Cancer Society. (2022, October 24). Thyroid Cancer Treatment. Retrieved from https://www.cancer.org/cancer/types/thyroid-cancer/treating.html

[7] U.S. Food & Drug Administration. (2022, March 1). Generics: Questions and Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generics-questions-and-answers

[8] U.S. Food & Drug Administration. (2015, August 24). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-compliance/current-good-manufacturing-practice-cgmp-regulations

[9] U.S. Food & Drug Administration. (2021, December 15). About Pharmacovigilance. Retrieved from https://www.fda.gov/safety/about-pharmacovigilance

[10] RxList. (n.d.). Levothyroxine Sodium. Retrieved from https://www.rxlist.com/levothyroxine-drug.htm (Note: Specific pricing data varies and is proprietary; cited for general information on levothyroxine pricing context).

[11] GoodRx. (n.d.). Levothyroxine Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/levothyroxine (Note: GoodRx provides consumer-level pricing; wholesale pricing is derived from broader market data and industry reports).

[12] Pharmaceutical industry market reports and data aggregation services (proprietary data). (2023-2024).